+Dr. Simon has received research support from Bristol-Myers Squibb, AstraZeneca, Cephalon, Forest Laboratories, GlaxoSmithKline, Janssen, Eli Lilly, NARSAD, NIMH, Pfizer, UCB Pharma, and Sepracor; she has served as an advisor and consultant to Paramount Biosciences and Solvay; and she has served as a speaker for Forest Laboratories, Janssen, Eli Lilly, Pfizer, UCB Pharma, and Sepracor. Dr. Pollack has served on the advisory boards of and as a consultant to Neurogen, Solvay, AstraZeneca, Brain Cells, Inc., Bristol-Myers Squibb, Cephalon, Forest Laboratories, GlaxoSmithKline, Janssen, Jazz Pharmaceuticals, Eli Lilly, Medavante, Neurocrine, Novartis, Otsuka, Pfizer, Predix, Roche Laboratories, Sanofi, Sepracor, Transoral Pharmaceuticals, UCB Pharma, Tikvah Therapeutics, and Wyeth; he has received research grants from Bristol-Myers Squibb, Cephalon, Forest Laboratories, GlaxoSmithKline, Janssen, Eli Lilly, NARSAD, NIDA, NIMH, Pfizer, Sepracor, UCB Pharma, and Wyeth; he has also served as a speaker for Bristol-Myers Squibb, Forest Laboratories, GlaxoSmithKline, Janssen, Eli Lilly, Pfizer, Solvay, and Wyeth; and he is a shareholder with Medavante and Mensante Corporation. Dr. Shear has served on the advisory board of or as a consultant to Pfizer and Forest Laboratories; and she has received research grants from Forest Laboratories. Ms. Thompson reports no competing interests.